GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

01

BEACON-HCC: Moving HCC Treatment Beyond Stage-Based Allocation: Hepatology | August 2026

Introduction: HCC treatment has traditionally been closely linked to staging systems such as BCLC. However, modern multidisciplinary care increasingly includes TARE, external-beam radiotherapy, systemic therapy, and combined approaches...

02

Perioperative Immunotherapy Is Redefining Curative-Intent HCC Treatment: JHEP Reports | September 2026

Introduction: Resection and liver transplantation remain the main curative-intent treatments for hepatocellular carcinoma (HCC), but recurrence after surgery is common and many patients present outside conventional surgical or...

03

What Comes After Atezolizumab–Bevacizumab in HCC: JHEP Reports | September 2026

Introduction: Immunotherapy-based combinations have transformed first-line treatment of unresectable HCC, but the optimal strategy after progression remains uncertain because no phase III trial has yet defined a standard...

04

EMERALD-3- STRIDE-Based Therapy Improves PFS in TACE-Eligible HCC: The Lancet | September 2026

Introduction: TACE remains a standard treatment for embolisation-eligible HCC, but recurrence and progression are common. Because TACE can enhance tumor antigen release and immune activation, combining it with...

05

Liver Resection After Atezo–Bev Improves Disease Control in Selected Advanced HCC (TALENTOP Trial): The Lancet | August 2026

Introduction: Systemic therapy has traditionally been the mainstay for HCC with macrovascular invasion. However, increasingly effective immunotherapy-based regimens can produce substantial tumor regression, raising an important question: should...

06

Atezolizumab–Bevacizumab in HCC - Real-World Benefit Extends Beyond Two Years: Hepatology | September 2026

Introduction: Atezolizumab plus bevacizumab (Atezo–Bev) transformed first-line treatment of unresectable hepatocellular carcinoma (HCC), but long-term follow-up from the pivotal IMbrave150 trial was limited. The prospective Italian ARTE study...

07

Can Blood-Based Biomarkers Replace Ultrasound for HCC Surveillance?: Hepatology Communications | August 2026

Introduction: Current HCC surveillance relies on ultrasound with AFP every 6 months, but ultrasound has limited sensitivity in patients with obesity or steatosis and real-world adherence remains suboptimal....

08

Integrating Portal Hypertension Into HCC Management: Nature Reviews Gastroenterology & Hepatology | August 2026

Introduction: Cirrhosis, portal hypertension, and hepatocellular carcinoma (HCC) are closely interconnected, yet clinical guidelines frequently approach portal hypertension and HCC as separate entities. This review proposes an integrated,...

09

Proportion of Time Covered (PTC) is A Better Measure of HCC Surveillance Quality: Gut | August 2026

Introduction: Regular surveillance is essential for the early detection of hepatocellular carcinoma (HCC) in high-risk patients, increasing the likelihood of curative treatment. However, real-world adherence to surveillance remains...

10

Methylation Plus AFP for Early HCC Detection: Hepatology Communications | July 2026

Introduction: Early detection of hepatocellular carcinoma (HCC) is critical for improving access to curative therapies, yet current surveillance with ultrasound and alpha-fetoprotein (AFP) has suboptimal sensitivity, particularly in...

Previous
128
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer